Personal information

No personal information available

Activities

Collapse all

Employment (9)

Universitat Ramon Llull: Barcelona, Catalunya, ES

2016-09 to present | Associate Professor Molecular Physiopathology (Bioengineering Department)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Universitat de Barcelona Facultat de Farmacia: Barcelona, Catalunya, ES

2016-09 to present | Associate Professor (Pharmacology, Toxicology and Chemical Therapeutics)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Universitat Pompeu Fabra Departament de Ciences Experimentals i de la Salut: Barcelona, Catalunya, ES

2005 to present | Associate Professor of Toxicology (Experimental and Health Sciences)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Prous Institute for Biomedical Research SA: Barcelona, Catalunya, ES

2010-03 to 2017-07-30 | Head Pharmacology (Pharmacology)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Palau Pharma SA: Palau-solita i Plegamans, Catalunya, ES

2001-09 to 2009-07 | Head of department (Pharmacokinetic and Bioanalysis Dept)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Lacer SA: Barcelona, Barcelona, ES

1997 to 2001 | Head of Department (Pharmacokinetics and Metabolism R & D)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Lacer SA: Barcelona, Barcelona, ES

1989 to 1997 | Head (Pharmacology and Animal Facilities R & D)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Institut Hospital del Mar d'Investigacions Mèdiques: Barcelona, Catalunya, ES

1986 to 1989 | PhD Student (Pharmacology & Toxicology Dept )
Employment
Source: Self-asserted source
Marcel·lí Carbó

Sanidad y Seguridad Social: Barcelona, Catalunya, ES

1985 to 1986 | General Practitioner (Ambulatorio Lope de Vega, Poble Nou)
Employment
Source: Self-asserted source
Marcel·lí Carbó

Education and qualifications (4)

Universitat Autònoma de Barcelona Facultat de Psicologia: Bellaterra, Catalunya, ES

2000-07 to present | Master Design and Statistics (Applied Statistics and Modeling Laboratory)
Education
Source: Self-asserted source
Marcel·lí Carbó

Universitat Autònoma de Barcelona Facultat de Ciències: Bellaterra, Catalunya, ES

1999-01 to present | Radioactive Facility Operator (Medicine and Industry qualification) (Radiation Physics Group. Department of Physics)
Education
Source: Self-asserted source
Marcel·lí Carbó

Universitat Autònoma de Barcelona Facultat de Medicina: Bellaterra, Catalunya, ES

1992-12-16 to present | Ph D (Pharmacology and Psychiatry)
Education
Source: Self-asserted source
Marcel·lí Carbó

Universitat Autònoma de Barcelona Facultat de Medicina: Bellaterra, Catalunya, ES

1984-06 | Degree in medicine and surgery
Education
Source: Self-asserted source
Marcel·lí Carbó

Funding (5)

Predicting Risk of Emerging Drugs with In silico and Clinical Toxicology (PREDICT)

2014-12 to 2017-01 | Grant
European Commission, Directorate-General Justice (Bruxelles, BE)
GRANT_NUMBER:

UST/2014/Action Grants (nº: 4000007082).

Source: Self-asserted source
Marcel·lí Carbó

Pharmacology, toxicology, pharmacokinetics and bioanalytical topics for the R&D projects in Prous Institute for Biomedical Research.

2010 to 2013 | Grant
Ministerio de Economía y Competitividad (Barcelona, ES)
Source: Self-asserted source
Marcel·lí Carbó

Pharmacokinetic and bioanalytical topics for the R&D projects in Uriach S.A., Uriach y Compañía S.A, and Palau Pharma.

2001 to 2009 | Grant
Ministerio de Economía y Competitividad (Barcelona, ES)
Source: Self-asserted source
Marcel·lí Carbó

Pharmacology, toxicology and pharmacokinetics topics for the R&D projects in Lacer, S.A.

1989 to 2001 | Grant
Ministerio de Economía y Competitividad (Madrid, ES)
Source: Self-asserted source
Marcel·lí Carbó

Mechanisms of action of caffeine metabolism inhibidors and their theoretical and practical importance ”

1986 to 1989 | Grant
CAYCIT (Institut Municipal d’Investigació Mèdica (IMIM, Barcelona), ES)
Source: Self-asserted source
Marcel·lí Carbó

Works (22)

Dose‐Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic Variation

Clinical Pharmacology & Therapeutics
2019-09 | Journal article
DOI: 10.1002/cpt.1417
Part of ISSN: 0009-9236
Part of ISSN: 1532-6535
Source: Self-asserted source
Marcel·lí Carbó

Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra‐articular administration

Drug Testing and Analysis
2019-06-17 | Journal article
DOI: 10.1002/dta.2614
Part of ISSN: 1942-7603
Part of ISSN: 1942-7611
Source: Self-asserted source
Marcel·lí Carbó

Metabolomics predicts the pharmacological profile of new psychoactive substances

Journal of Psychopharmacology
2019-03 | Journal article
DOI: 10.1177/0269881118812103
Part of ISSN: 0269-8811
Part of ISSN: 1461-7285
Source: Self-asserted source
Marcel·lí Carbó

Pharmacokinetics in morbid obesity: influence of two bariatric surgery techniques on paracetamol and caffeine metabolism

Obesity Surgery
2017 | Journal article
Source: Self-asserted source
Marcel·lí Carbó

The concentration of MDPV in rat striatum correlate with the psychostimulant effect

J Psychopharmacology
2015 | Journal article
DOI: 10.1177/0269881115598415
Source: Self-asserted source
Marcel·lí Carbó

An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts"

Prog Neuropsychopharmacol Biol Psychiatry
2013 | Journal article
DOI: 10.1016/j.pnpbp.2013.04.007
Source: Self-asserted source
Marcel·lí Carbó

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart

Psychopharmacology (Berl)
2013 | Journal article
DOI: 10.1007/s00213-012-2894-7
Source: Self-asserted source
Marcel·lí Carbó

Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics.

Psychopharmacology (Berl)
2013 | Journal issue or edition
DOI: 10.1007/s00213-013-3108-7
Source: Self-asserted source
Marcel·lí Carbó

Changes in CYP1A2 activity in 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) metabolism using caffeine as probe drug in humans

Drug Metab Pharmacokinet
2012 | Journal article
PMID: 22673010
Source: Self-asserted source
Marcel·lí Carbó

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)

Plos One
2012 | Journal article
DOI: 10.1371/journal.pone.0047599
Source: Self-asserted source
Marcel·lí Carbó

Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: implications for doping control analysis of these stimulants banned in sport"

Drug Testing and Analysis
2012 | Journal article
DOI: 10.1002/dta.291
Source: Self-asserted source
Marcel·lí Carbó

Gender differences in 3,4-methylenedioxymetamphetamine (MDMA, ectasy) induced CYP2D6 inhibition in humans

Clin Pharmacokinet
2011 | Journal article
DOI: 10.2165/11584550-000000000-00000
Source: Self-asserted source
Marcel·lí Carbó

Animales de Laboratorio

Animales de laboratorio
2009 | Journal article
Source: Self-asserted source
Marcel·lí Carbó

Historia de los Laboratorios Uriach

Actualidad en Farmacología y Terapéutica
2009 | Journal article
Source: Self-asserted source
Marcel·lí Carbó

Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs

The Veterinary J
2009 | Journal article
DOI: 10.1016/j.tvjl.2008.03.001
Source: Self-asserted source
Marcel·lí Carbó

Antihistaminic effects of rupatadine and PKPD modelling

Eur J Drug Metabolism Pharmacokin
2008 | Journal article
PMID: 18777946
Source: Self-asserted source
Marcel·lí Carbó

Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady state levels: a randomized, open-label, two-way, crossover phase I study.

Clin Ther
2008 | Journal article
DOI: 10.1016/j.clinthera.2008.09.002
Source: Self-asserted source
Marcel·lí Carbó

Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: A single-dose, randomized, open-label, two-way crossover study

Clin Ther
2007 | Journal article
DOI: 10.1016/j.clinthera.2007.05.004
Source: Self-asserted source
Marcel·lí Carbó

Quinolone inhibition of caffeine disposition in humans.

Eur J Clin Pharmacol
1990 | Journal article
PMID: 2177401
Source: Self-asserted source
Marcel·lí Carbó

Caféine, données de base et facteurs capables de la modifier.

Science et Sport
1989 | Journal article
Source: Self-asserted source
Marcel·lí Carbó

Quinolone effect on caffeine disposition.

Clin Pharmacol Ther
1989 | Journal article
PMID: 2920498
Source: Self-asserted source
Marcel·lí Carbó

Automatic determination of M.E.P. patterns of molecules and its application to caffeine metabolism inhibitors.

J Mol Struc (TEOCHEM)
1988 | Journal article
Source: Self-asserted source
Marcel·lí Carbó
How many people are using ORCID?